Use of Sulfonylureas may increase risk of dementia among diabetes patients
A study published in the Journal of the American Geriatrics Society has provided evidence that sulfonylureas, especially glyburide, maybe a suboptimal choice for cognitive longevity in older adults. They highlighted that Type 2 diabetes is a risk factor for dementia, which the choice of oral glucose-lowering drugs may influence.
Che-Yuan Wu BSc explained the findings in the study entitled “Association of sulfonylureas with the risk of dementia: A population-based cohort study”.
It is already known that Sulfonylureas are oral glucose-lowering medications. These are the second-line therapy for type 2 diabetes. There is mixed evidence available relating them to cognitive decline.
In the present study, researchers determined whether sulfonylurea use is associated with a differential risk of dementia compared with a dipeptidyl peptidase-4 (DPP4) inhibitor. Researchers used administrative data from residents in Ontario, Canada, adults aged ≥66 years who were new users of a sulfonylurea or a DPP4 inhibitor from June 14, 2011, to March 31, 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.